Compare Abbott Laboratories (ABT) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Warner Music Group Corp — how do they compare? Abbott Laboratories trades at $109.28 (market cap $187.95B), while Warner Music Group Corp trades at $25.02 (market cap $13.12B). The key difference: Abbott Laboratories is far larger — about 14.3× Warner Music Group Corp's market cap, and Warner Music Group Corp pays the higher dividend (3.19%). Which is the better fit depends on your goals.
| ABT | WMG | |
|---|---|---|
Market Cap | $187.95B | $13.12B |
Sector | Health | Media |
52-Week High | $136.62 | $34.72 |
52-Week Low | $82.57 | $23.65 |
Enterprise Value | $214.96B | $17.42B |
Dividend Yield | 2.32% | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
Warner Music Group (WMG) trades at $26.41, up 0.08% on the day, with a bearish technical signal but improving fundamentals. Recent earnings beat expectations in Q1 and Q2 2026, with revenue growth to $7.3B projected for 2026. The stock shows a P/E of 20.06 and net income margin of 9.2%, supported by strong cash flow and dividend payments. Key resistance is at $27, with support at $26.
WMG presents a mixed outlook: bullish fundamentals with earnings beats and growth, but technicals indicate near-term pressure. Opportunities include streaming expansion and AI integration, while risks involve leadership changes and market volatility. Analyst consensus is 66.7% buy, suggesting long-term value if technical resistance is overcome.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
